Publications & Talks

Shortcuts: 2013 2012 2011 2010 2009 2008 2007 2006 2005

2013
	Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally, or Globally: An Analysis from the POSEIDON Trial, American College of Cardiology Scientific Sessions 2013
	An Open Label Dose Escalation Study to Evaluate the Safety of Administration of Non-Viral SDF-1 Plasmid to Treat Symptomatic Ischemic Heart Failure
Poster	Quantifying therapeutic cell retention in the heart to compare three routes of local delivery: Transendocardial Intramyocardial Injection, Transepicardial Intramyocardial Injection, and Intracoronary Artery Infusion, 8th International Conference on Cardiovascular Cell Therapy 2013
Poster	Training on Transendocardial Delivery: The Helical Infusion System Experience, 8th International Conference on Cardiovascular Cell Therapy 2013
Talk	Peter Altman of BioCardia, “The Helical Infusion System”, 8th International Conference on Cardiovascular Cell Therapy 2013

2012
	Comparison of Allogeneic vs Autologous BoneMarrow–DerivedMesenchymal StemCells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy The POSEIDON Randomized Trial. JAMA. 2012;308(22)
	Assessment of Safety, Accuracy, and Human CD34+ Cell Retention After Intramyocardial Injections with a Helical Needle Catheter in a Porcine Model, Cardiovascular Catheterization & Intervention 2012
Talk	Dr. Marc Penn of Juventas Therapeutics: “Re-Establishment Of SDF-1 Expression Through Non-Viral Gene Therapy Improves Clinical Parameters Through 12 Months In Patients With Ischemic Class III Heart Failure”, 16th Annual Scientific Meeting Heart Failure Society of America 2012
Poster	Stem Cell Injection Can Reverse The Left Ventricular Spherical Remodeling Of Ischemic Cardiomyopathy: Turning Soccer Balls Into (American) Footballs. American College of Cardiology 2012, Abstract 1221-372.
Presentation	SDF-1 for Heart Failure: One-Year Results of a Phase I trial, 7th International Conference on Cell Therapy for Cardiovascular Disease, NYC, NY Jan25-27, 2012, (Marc Penn, MD, PhD).

2011
	De la Fuente LM, Stertzer SH, Argentieri J, Penaloza E, Rouy D, Altman PA. Transendocardial Autologous Bone Marrow in Myocardial Infarction Induced Heart Failure, Two Year Follow up in an Open Label Phase I Study, Eurointervention 2011; 7:805-812.
Talk	Helix transendocardial delivery catheter system, safety and ease of use after 100+ cases, David Snow (BioCardia, San Carlos, USA) presented at the 8th International Symposium on Stem Cell Therapy and Cardiovascular Innovation, Madrid, Spain, June 9-10, 2011
Poster	"Five Year Follow-up in Heart Failure Safety Study of Transendocardial Autologous Bone Marrow Cell Therapy Delivered using Helical Infusion System Provides First Data that Supports Reduced Mortality" Luis M. de la Fuente, M.D., Simon H. Stertzer, M.D.¥, Julio Argentieri, M.D., Eduardo Peñaloza, M.D., Benjamin Koziner, M.D., Cheryl Wong Po Foo, Ph.D.§, Didier Rouy, M.D Ph.D.§, Peter A. Altman, Ph.D.§ *Instituto Argentino de Diagnostico y Tratamiento and Clinica Suizo Argentina, Buenos Aires, Argentina, ¥Stanford University Medical Center, Stanford, CA, §BioCardia Inc., San Carlos, CA, presented at the 8th International Symposium on Stem Cell Therapy & Cardiovascular Innovations, Madrid, Spain, June 9-10 2011.
Article	Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz,R, Mendizabal A, Oskouei B, Byrnes J, Soto V, Tracy M, Zambrano JP, Heldman AW, and Hare JM. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J 2011;161:487-93.
Presentation	De la Fuente LM, Stertzer SH, Argentieri J, Peñaloza E, Miano J, Koziner B, Bilos C, L Battaglia, G Lucero, Stertzer J, Rouy D, Altman PA. Five Year Follow-up in Heart Failure Safety Study of Transendocardial Autologous Cell Therapy Derived from Bone Marrow Delivered using Helical Infusion System Provides First Data that Supports Reduced Mortality, Catheterization & Cardiovascular Interventions, F-030, Suppl Vol 77 Issue 6, May 1, 2011.
Presentation	Penn MS, Pastore J, Aras R, Rouy D, Schaer G, Farr MJ, Sherman W, Mendelsohn F, and Losordo D. Initial Results from First –In Man Study Delivering Non-Viral Gene Therapy JVS -100 to Treat Ischemic Heart Failure., American Society of Gene and Cell Therapy, 14th Annual Meeting, May 2011.
Article	“Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy Functional Recovery and Reverse Remodeling” Adam R. Williams, Barry Trachtenberg, Darcy L. Velazquez, Ian McNiece, Peter Altman, Didier Rouy, Adam M. Mendizabal, Pradip M. Pattany, Gustavo A. Lopera, Joel Fishman, Juan P. Zambrano, Alan W. Heldman, Joshua M. Hare Circ Res. 2011;108:792-796.

2010
Poster	“Intra-myocardial administration of JVS-100 promotes cardiac benefit and improves angiogenesis in a porcine model of heart failure” by Joseph M Pastore, Ph.D, Timothy J Miller, Ph.D, Rahul A Aras, Ph.D, and Marc S Penn, Ph.D, MD. - Juventas Therapeutics and Dept. of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland OH
Article	Recommendations for Successful Training on Methods of Delivery of Biologics for Cardiac Regeneration: A Report of the International Society for Cardiovascular Translational Research by Nabil Dib, Philippe Menasche, Jozef J. Bartunek, Andreas M. Zeiher, Andre Terzic, Nicolas A. Chronos, Timothy D. Henry, Nicholas S. Peters, Francisco Fernández-Avilés, Magdi Yacoub, Timothy A. Sanborn, Anthony DeMaria, Richard A. Schatz, Doris A. Taylor, Shmuel Fuchs, Silviu Itescu, Leslie W. Miller, Jonathan H. Dinsmore, George D. Dangas, Jeffrey J. Popma, Jennifer L. Hall, and David R. Holmes, Jr., J. Am coll. Cardiol. Intv. 2010;3;265-275 doi:10.1016/j.jcin.2009.12.013
2009
Talk	Transcatheter Cardiovascular Therapeutics, San Francisco, September 2009. Featured in lecture entitled "Clinical Insights to Cell Delivery: Case Demonstrations" by Dr. Alan W. Heldman.
Talk	New Cardiovascular Horizons, New Orleans, LA, June, 2009. Featured in lecture entitled "The role of the cardiologist in myocardial regeneration" by Dr. Juan Pablo Zambrano.
Poster	Cardiac Research Technologies, New York City, March 4-6, 2009. "Three Year Follow-up in an Open-Label, Pilot Study of Transendocardial Autologous Bone Marrow in Chronic Myocardial Infarction using a Helical Needle Catheter"
Talk	The Fifth International Conference on Cell Therapy For Cardiovascular Disease, New York City, January 13-16. Featured in lecture entitled "CD34+ Cells for Combined CHF and Angina" by Gary L. Schaer, M.D.
Talk	Fifth International Conference on Cell Therapy For Cardiovascular Disease, New York City, January 13-16. Featured in lecture entitled "Novel Catheter Techniques in the Acute Setting" by Warren Sherman, M.D.
Talk	Fifth International Conference on Cell Therapy For Cardiovascular Disease, New York City, January 13-16. Featured in lecture entitled "MSCs for Congestive Heart Failure: Surgical and Catheter Applications" by Alan W. Heldman, M.D.
2008
Abstract	Transcatheter Cardiovascular Therapeutics 2008, Washington D.C., October 12-17. Abstract entitled "Accuracy and Safety of Transendocardial Intramyocardial Injections Using a Fluroscopically-Guided Deflectable Guiding Catheter and a Novel Helix-tipped Dual-Lumen Injection Catheter in a Porcine Model" by Dr. Gary Schaer was presented.
Talk	Transcatheter Cardiovascular Therapeutics 2008, Washington D.C., October 12-17. Featured in talk by Dr. Marc Penn, Director of Technology, Cleveland Clinic Foundation, and founder of AcelleRx, Inc on studies of SDF-1 Plasmid delivered in which dosing in swine showed efficacy at 30 days is positive using BioCardia Helix catheteter.
Talk	Transcatheter Cardiovascular Therapeutics 2008, Washington D.C., October 12-17. Featured in talk by Dr. Joshua Hare, Chief of Cardiology, University of Miami on his talk on Mesenchymal Stem Cells in ST elevated myocardial infarction.
Talk	New Cardiovascular Horizons 2008, New Orleans, LA, September 9-13. Featured in “Combining A Novel Cell Delivery System With Regenerative Therapy – Results Of The TAC-HRT Phase I Trial” by Alan Heldman, M.D.
	Transendocardial Autologous Bone Marrow in Chronic Myocardial Infarction using a Helical Needle Catheter, Two Year Follow-up in an Open-Label, Non-Randomized, Pilot Study (the TABMMI study) Presented at the 2008 World Congress of Cardiology Abstracts, Buenos Aires, Argentina, May 2008.
	Transendocardial Autologous Bone Marrow Cells in Chronic Myocardial Infarction using Helical Needle Catheter: Two-Year Followup in an Open-Label, Non-Randomized, Single-Center Pilot Study (the TABMMI study) By Luis M. de la Fuente, M.D., Simon H. Stertzer, M.D., Eduardo Peñaloza, M.D., Julio Argentieri, M.D., Jorge Miano, M.D., Benjamin Koziner, M.D., Christian Bilos, M.D., Licia Battaglia, Ph.D., Graciela Lucero, Ph.D., Jessica Stertzer, Didier Rouy, M.D., Peter A. Altman, Ph.D. Presented at the Cardiovascular Revascularization Therapies (CRT) conference, Washington, D.C., February 12, 2008.
	Reporter Gene Imaging Following Percutaneous Delivery in Swine: Moving Toward Clinical Applications. By Martin Rodriguez-Porcel,M.D., Todd J. Brinton, M.D., Ian Y. Chen, MSE, Olivier Gheysens, M.D., Jennifer Lyons, Fumiaki Ikeno, M.D., Jürgen K. Willmann, M.D., Lily Wu, M.D., Ph.D., Joseph C. Wu, M.D., Ph.D., Alan C. Yeung, M.D., Paul Yock, M.D., and Sanjiv J. Gambhir, M.D., Ph.D. Published in the Journal of the American College of Cardiology, February 5, 2008.

2007
Poster	American Heart Association Council on Basic Cardiovascular Sciences, July 30-Aug 2, Keystone, CO: "Transendocardial Catheter Delivery of Artificial Biopolymer Matrices for Enhanced Cell Retention in Cardiovascular Cell Based Therapy"
	Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study) - American Heart Journal, July 2007
Poster	The Stem Cell Meeting, March 2007, San Francisco, CA: “Transendocardial Autologous Bone Marrow Cells in Chronic Myocardial Infarction Using Helical Needle Catheter, Six Month Follow-up in an Open-Label, Non-Randomized, Single-Center Pilot Study of an Adult Stem Cell Stimulation Program (the TABMMI Study)” by Luis De La Fuente, et. al.
Invited Talk	Percutaneous Endovascular Therapeutics, April 2007, Buenos Aires, Argentina: “Percutaneous Cardiovascular Cell Therapy”
Talk	2nd Annual Symposium on Cardiovascular Cell Therapy 2007: Featured in ‘Clinical Studies II: Chronic Left Ventricular Dysfunction “Bone Marrow Mononuclear Cells: The Focus – CHF Study” by Dr. Emerson Perin

2006
	Six Month Follow-up after Transendocardial Autologous Fractionated Bone Marrow Shows Increased Ejection Fraction in Patients with Ventricular Dysfunction After Chronic Myocardial Infarction, an Open-Label, Non-Randomized, Single-Center Study (the TABMMI study)
	Catheter-based delivery of cells to the heart
	Percutaneous delivery and non-invasive imaging of gene and cell therapy in a porcine model
Talk	Transcatheter Cardiovascular Therapeutics 2006: Featured in “Novel Myocardial Preservation Therapies” in Plenary Session 15: Interventional Hot Topics V by Dr. Bill O’Neil
Talk	Transcatheter Cardiovascular Therapeutics 2006: Featured in “Isolation and Potential of Cardiac-Derived Stem Cells” in Session on Myocardial Repair Strategies: From Local Responses to Cell Therapy to Tissue Engineering by Dr. Joshua Hare.
Talk	Transcatheter Cardiovascular Therapeutics 2006: Featured in “Cell Retention” Routes of Cell Delivery by Dr. Dara L. Kraitchman.

2005
	Coronary intervention, Vol. 1 No. 3 2005, pp. 95-97 (Japanese)
	Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction, PNAS, Aug., 2005

2004
	Cardiac Repair with Mesenchymal Stem Cells following Myocardial Infarction in Pigs
	American Heart Association Scientific Sessions 2004: Featured in: "Overview of Cell Based Therapies," by Dr. Joshua Hare, Baltimore, MD.
	Transcatheter Cardiovascular Therapeutics 2004: Featured in “Intracoronary vs. Percutaneous Endomyocardial Delivery of Porcine Mesenchymal Stem Cells to Areas of Myocardial Infarction,” by Dr. Eric Price, Stanford University.

2003
	In Vivo Magnetic Resonance Imaging of Mesenchymal Stem Cells in Myocardial Infarction
	Percutaneous Endocardial Versus Selective Coronary Venous Cellular Delivery: Comparison of Transplant Efficiency, Distribution, and Efficacy in Reducing Infarct Size and Improving Myocardial Function
	Catheter Based Percutaneous Cardiomyoplasty Using Allogenic Bone Marrow Derived Mesenchymal Stem Cells
	How Well Does A Helical Needle Catheter Deliver FGF-2?
	Intramyocardial Pharmacokinetics of Cell Sized Particles after Local Transendocardial Delivery in Swine
	Exploring Heart Lymphatics in Local Drug Delivery

2002
	The Helical Infusion Catheter: First Clinical Evaluation for Local Intramyocardial Delivery of Therapeutics
	Preparation and Administration of Biodegradable Drug Delivery Microspheres into Porcine Myocardium with a Helical Injection Catheter
	Interventional Cellular Cardiomyoplasty by Transendocardial Implantation of Mesenchymal Stem Cells
	Delivery of Plasmid to the Myocardium Using Direct Injection Via Needle or Helical Needle-Catheter
	Percutaneous Endocardial Infusion of Plasmids Using Helical Needle Catheter

2001
	Percutaneous Intramyocardial Delivery is an Efficient Modality for Local Myocardial Treatment
	Transcatheter Delivery of Therapeutic Formulations For Percutaneous Intramyocardial Delivery
	Enhanced Local Uptake of Genetic Material Through Intramyocardial Electroporation with Helix Infusion Electrode
	Evaluation of the Percutaneous Intramyocardial Injection for Local Myocardial Treatment

2000
	Feasibility Studies of Percutaneous Mammalian Cell Delivery for Local Myocardial Treatment